Leber’s Hereditary Optic Neuropathy (LHON) Market

1. Leber’s Hereditary Optic Neuropathy (LHON) Market Leber’s Hereditary Optic Neuropathy (LHON)is a distinct type of “inherited optic atrophies” or “hereditary optic neuropathies.” It refers to an optic nerve dysfunction due to point mutations in the mitochondrial DNA and is transmitted in non-mendelian pattern. DelveInsight's "Leber's Hereditary Optic Neuropathy (LHON) - Market Insights, Epidemiology, and Market Forecast-2030" report delivers an in-depth understanding of the Leber's Hereditary Optic Neuropathy (LHON) , historical and forecasted epidemiology as well as the Leber's Hereditary Optic Neuropathy (LHON) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. Geography Covered    The United States EU5 (Germany, France, Italy, Spain, and the United Kingdom) Japan Study Period:2017-2030 View detailed report @https://www.delveinsight.com/report-store/lebers-hereditary-optic- neuropathy-lhon-market Leber's Hereditary Optic Neuropathy (LHON) Disease Understanding and Treatment Algorithm The primary cell type lost in LHON is the retinal ganglion cell, which is highly susceptible to disrupted ATP production and oxidative stress. Inheritance of LHON follows the mitochondrial genetics, and it has a highly variable clinical phenotype, as other genetic and environmental factors also play a role. It is characterized by bilateral subacute loss of central vision due to focal degeneration of the retinal ganglion cell layer and optic nerve. LHON most commonly presents as painless loss of central vision in one eye, followed rapidly by loss of vision in the other eye within a few months. In some cases, both eyes

2. will be affected from the onset. It can have both ophthalmologic and extra-ocular features. Ophthalmologic manifestations can further be subdivided into the acute phase and chronic phase. LHON is maternally inherited, and both male and female offspring can inherit the mutation, yet 50% of males and only 10% of females experience vision loss. Also, it has been hypothesized that there is a recessive X-linked susceptibility gene that works in concert with the mitochondrial mutation, which could explain the male predominance among carriers who lose vision. The DelveInsight Leber's Hereditary Optic Neuropathy (LHON) market report gives a thorough understanding of the Leber's Hereditary Optic Neuropathy (LHON) by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis and treatment. Leber's Hereditary Optic Neuropathy (LHON) Epidemiology The Leber's Hereditary Optic Neuropathy (LHON) epidemiology division provide insights about historical and current Leber's Hereditary Optic Neuropathy (LHON) patient pool and forecasted trend for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken. Key Findings  The prevalence of LHON is thought to be around 1/50,000 people worldwide.  The disease affects approximately 10,000 people in the United States and can lead to legal blindness.  The prevalence of LHON has been well established in Northern European populations with figures ranging from 1/30,000 to 1/50,000. The disease epidemiology covered in the report provides historical as well as forecasted Leber's Hereditary Optic Neuropathy (LHON) epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030. Request for sample pages: https://www.delveinsight.com/sample-request/lebers-hereditary- optic-neuropathy-lhon-market Leber's Hereditary Optic Neuropathy (LHON) Drug Chapters Key players, such as GenSight, Stealth BioTherapeutics, and others,arein the process of developing potential therapies for the treatment of Leber’s hereditary optic neuropathy (LHON). The launch of emerging therapies, such as GS010 (GenSight), Elamipretide (Stealth BioTherapeutics), andothers, are expected to significantly impact the treatment scenario of Leber’s Hereditary Optic Neuropathy (LHON) in the upcoming years. Drug chapter segment of the Leber's Hereditary Optic Neuropathy (LHON) report encloses the detailed analysis of Leber's Hereditary Optic Neuropathy (LHON) marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the Leber's Hereditary Optic Neuropathy (LHON) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.

3. Leber's Hereditary Optic Neuropathy (LHON) Market Outlook The mainstay of clinical treatment for Leber’s hereditary optic neuropathy (LHON)remains supportive rather than curative. The management of LHON patients includes low vision aids, occupational rehabilitation, and registration with local social services. Those with mitochondrial mutations should be advised to refrain from smoking and binge alcohol drinking. Furthermore, screening for extraocular manifestations should be carried out in the form of an electrocardiogram and complete neurological evaluation. The Leber's Hereditary Optic Neuropathy (LHON) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Leber's Hereditary Optic Neuropathy (LHON) markettrends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. According to DelveInsight, Leber's Hereditary Optic Neuropathy (LHON) market in 7MM is expected to change in the study period 2017-2030. Download sample pages: https://www.delveinsight.com/sample-request/lebers-hereditary- optic-neuropathy-lhon-market